Kevin Outterson
Boston University
H-index: 37
North America-United States
Top articles of Kevin Outterson
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
The Law of American Health Care:[Connected EBook] | Nicole Huberfeld Elizabeth Weeks Leonard Kevin Outterson Matthew Lawrence | 2023/2/20 | |
Global pull incentives for better Antibacterials: the UK leads the way | Applied Health Economics and Health Policy | Kevin Outterson John H Rex | 2023/5 |
Trends in the global antibiotics market | Jacob Madden Kevin Outterson | 2023/3/1 | |
Patient access in 14 high-income countries to new antibacterials approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and … | Clinical Infectious Diseases | Kevin Outterson Ebiowei SF Orubu John Rex Christine Årdal Muhammad H Zaman | 2022/4/1 |
Antimicrobial resistance: what’s at stake and what are we doing about it? | Health Affairs Forefront | Kevin Outterson Helen W Boucher Aleks Engel Rena M Conti Gabriela Gracia | 2022 |
A pandemic instrument can start turning collective problems into collective solutions by governing the common-pool resource of antimicrobial effectiveness | Journal of Law, Medicine & Ethics | Isaac Weldon Kathy Liddell Susan Rogers Van Katwyk Steven J Hoffman Timo Minssen | 2022 |
Introduction: AMR Belongs in the Pandemic Instrument | Journal of Law, Medicine & Ethics | Susan Rogers Van Katwyk Kevin Outterson | 2022 |
Antimicrobial resistance: is health technology assessment part of the solution or part of the problem? | Value in Health | Abigail R Colson Alec Morton Christine Årdal Kalipso Chalkidou Sally C Davies | 2021/12/1 |
Antibiotic development incentives that reflect societal value of antibiotics | Clinical Infectious Diseases | Helen W Boucher Thomas M File Vance G Fowler Amanda Jezek John H Rex | 2021/5/1 |
Antibacterial R&D at a crossroads: we’ve pushed as hard as we can… now we need to start pulling! | John H Rex Kevin Outterson | 2021/12/1 | |
Improving data sharing to increase the efficiency of antibiotic R&D | Wes Kim Kevin Krause Zak Zimmerman Kevin Outterson | 2021/1 | |
Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines: Study examines global antibacterial pull incentives. | Health Affairs | Kevin Outterson | 2021/11/1 |
Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward | Amila K Nanayakkara Helen W Boucher Vance G Fowler Jr Amanda Jezek Kevin Outterson | 2021/11 | |
The impact of infections on reimbursement in 92 US hospitals, 2015-2018 | American Journal of Infection Control | Laura Puzniak Vikas Gupta C Yu Kalvin Gang Ye Kevin Outterson | 2021/10/1 |
The effect of generic market entry on antibiotic prescriptions in the United States | Nature communications | Cecilia Kållberg Jemma Hudson Hege Salvesen Blix Christine Årdal Eili Klein | 2021/5/18 |
Setting the agenda for social science research on the human microbiome | Palgrave Communications | Beth Greenhough Cressida Jervis Read Jamie Lorimer Javier Lezaun Carmen McLeod | 2020/1/31 |
Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy | Claas Kirchhelle Paul Atkinson Alex Broom Komatra Chuengsatiansup Jorge Pinto Ferreira | 2020/9/1 | |
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization | Kevin Outterson John H Rex | 2020/6/1 | |
The global preclinical antibacterial pipeline | Ursula Theuretzbacher Kevin Outterson Aleks Engel Anders Karlén | 2020/5 | |
Social, cultural and economic aspects of antimicrobial resistance | Bulletin of the World Health Organization | Timo Minssen Kevin Outterson Susan Rogers Van Katwyk Pedro Henrique D Batista Clare IR Chandler | 2020/12/12 |
Co-Authors
